RecruitingNot ApplicableNCT05082961

Circulating Immunes Cells, Cytokines and Brain Radiotherapy


Sponsor

Centre Francois Baclesse

Enrollment

40 participants

Start Date

Jan 27, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Patients with malignant tumours of the cephalic pole have a poor prognosis, despite a wide range of treatments. prognosis despite a large therapeutic arsenal. Among this arsenal, radiotherapy (RT) is one of the standard treatments for these tumours. However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic tissue and can promote pro-tumour inflammation. In these circumstances, hadrontherapy, which uses charged heavy particles, such as protons or carbon ions, is the preferred treatment. protons or carbon ions, seems more appropriate for the treatment of these tumours. However, although inflammation plays a major role in tumour development and tumour development and therapeutic response, few studies have evaluated the immune response response after proton therapy (PT) and carbon therapy (CT). The objective of this project is to study the effect of hadrontherapy on resident/circulating inflammation after brain irradiation. brain irradiation. In a first step, the impact of different PT and CT TEL on macrophages (M\Ф), the most abundant immune cells in malignant solid tumours, will be evaluated in vitro. malignant solid tumours, will be evaluated in vitro. In a second step, the evolution of circulating leukocytes after brain irradiation with X-rays or protons will be studied in vivo in rodents and patients. rodent and patient. In this project, we propose to study for the first time the inflammatory response after hadrontherapy in the context of a cephalic tumour. cephalic tumour. These results will allow a better understanding of the biological response response following PT and CT with the aim of optimising RT and potentially and potentially translate these data to the clinic.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is measuring immune cells and proteins in the blood of people with head and neck cancer who are receiving radiation therapy after surgery, to understand how radiation affects the immune system over time. **You may be eligible if...** - You are 18 or older - You have been diagnosed with head or neck cancer (including throat, sinus, nasal cavity, skull base, or brain tumors) and have had surgery to remove it - Your surgery achieved a complete or near-complete removal of the tumor - You are scheduled to receive radiation therapy (at least 54 Gy) as your sole post-operative treatment (no concurrent chemotherapy) - You are affiliated with a social security scheme **You may NOT be eligible if...** - There is visible tumor remaining after surgery (gross residue) - You have had a prior cancer within the last 5 years - You have had prior radiation to the head or neck area - You are receiving concurrent chemotherapy or cetuximab with radiation - You are on long-term immunosuppressants or steroids - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERCollection of blood samples

Samples to evaluate the circulating CD8+ T cell count.


Locations(1)

Centre François Baclesse

Caen, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05082961


Related Trials